New indigenously developed Human Papillomavirus (HPV) test kits for cervical cancer screening were officially launched in Delhi on Wednesday, April 23, 2025.
These test kits have been created under the Department of Biotechnology라이브 바카라 (DBT) Grand Challenges India (GCI) initiative, in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC).
The DBT supported research coordinated by the All India Institute of Medical Sciences (AIIMS) Delhi, with testing done at laboratories at AIIMS, National Institute of Cancer Prevention and Research (NICPR), Noida; and the National Institute for Research in Reproductive and Child Health (NIRRCH), Mumbai, in collaboration with World Health Organisation (WHO) International Agency for Research on Cancer (IARC).
"The key feature of these kits is the inclusion of only the seven-eight most common cancer-causing types that will allow a very efficient and cost-effective screening programme which will be most suitable for India," Dr Neerja Bhatla, former head of the department of Obstetrics and Gynaecology at AIIMS, Delhi and chief coordinator of the programme said.
The study titled 'Validation of Indigenous Human Papillomavirus Tests for Cervical Cancer Screening in India (i-HPV)' validated indigenously developed, rapid, point-of-care, RTPCR-based HPV diagnostic test kits for screening cervical cancer in premier research and development laboratories of India.
"Given the enhancement of RTPCR-based diagnostic facilities across the nation in the post-COVID era, the introduction of sensitive RTPCR-based HPV testing kits might prove to be cost effective screening method over classical HPV DNA and Pap smear for deployment in the national cancer screening programme," Dr Bhatla said.
